Company Overview of Perosphere Inc.
Perosphere Inc., a specialty pharmaceutical company, provides drug delivery technology. Its drug delivery technology enables localized and systemic delivery, alters pharmacokinetics and pharmacodynamics to improve controlled release formulations, and reduces inter and intra-patient variability. The company’s drug delivery technology is used in drug candidates, such as PER726, an intravenous therapeutic drug; PER921 and PER922, which are oral solid dose therapeutic drugs; PER923, a low dose administration of a therapeutic drug; PER1080, a rapid-acting formulation of a therapeutic drug; and PER977 to reverse the anticoagulant activity of unfractionated heparin, low molecular weight heparins, f...
24 Old Wagon Road
Bedford, NY 10549
Founded in 2011
Key Executives for Perosphere Inc.
Founder, Chairman, Chief Executive Officer and President
Founder, Chief Technology Officer and Vice President
Founder and Vice President of Research
Founder and Chief Scientific Officer
Chief Financial Officer, Vice President of Finance and Treasurer
Compensation as of Fiscal Year 2014.
Perosphere Inc. Key Developments
Perosphere Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
Perosphere Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Perosphere Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Perosphere Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Perosphere Inc. Receives FDA IND Clearance to Initiate Clinical Investigations of the Safety and Efficacy of PER977
May 22 13
Perosphere Inc. announced that it has received U.S. Food and Drug Administration investigational new drug clearance to initiate clinical investigations of the safety and efficacy of PER977 to reverse the anticoagulant activity of unfractionated heparin, low molecular weight heparins, fondaparinux, and factor Xa- and IIa-inhibitors. PER977 has demonstrated the ability to reverse the anticoagulant effects of unfractionated heparin, low molecular weight heparins, fondaparinux, and factor Xa- and IIa-inhibitors in vitro in animal models and ex vivo in human blood. Perosphere will initially test the ability of PER977 to reverse the anticoagulant activity of edoxaban in a Phase I clinical trial. Daiichi Sankyo Company, Limited is developing edoxaban, an investigational, oral, once-daily anticoagulant that specifically and reversibly inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting. Perosphere and Daiichi Sankyo have previously announced that Daiichi Sankyo is co-sponsoring the Phase I clinical trial. The clinical trial will be conducted by the Duke Clinical Research Unit, the early-phase unit of the Duke Clinical Research Institute at the Duke University School of Medicine.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|